Study Title
Phase II study of SPI-1620 in combination with docetaxel as a second-line treatment for patients with advanced biliary cancer
Malignancy
Bile Duct, Gallbladder, Biliary Tract
Drug Class
Endothelin B (ETB) agonist
Key Eligibility Criteria Details
Histologically confirmed biliary tract or gallbladder cancer
Failure of one prior gemcitabine-based chemo regimen
ECOG PS 0-2
No uncontrolled CNS mets
No significant circulatory disorders in last 6 months
No conmed of phosphodiesterase inhibitor
No high-grade baseline peripheral neuropathy
Objective
Primary- PFS: Secondary- ORR, OS, DoR, Safety